{"id":32697,"date":"2025-04-09T12:26:22","date_gmt":"2025-04-09T10:26:22","guid":{"rendered":"https:\/\/ggba.swiss\/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform\/"},"modified":"2025-04-09T12:29:09","modified_gmt":"2025-04-09T10:29:09","slug":"novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/","title":{"rendered":"Novigenix obtient EUR 1,8 million pour d\u00e9velopper sa plateforme d&rsquo;oncologie de pr\u00e9cision"},"content":{"rendered":"\n<p><a href=\"https:\/\/novigenix.com\/\">Novigenix<\/a>, une soci\u00e9t\u00e9 bas\u00e9e au<a href=\"https:\/\/www.biopole.ch\/\"> Biop\u00f4le<\/a> \u00e0 Lausanne et sp\u00e9cialis\u00e9e dans l&rsquo;oncologie de pr\u00e9cision bas\u00e9e sur l&rsquo;IA, a re\u00e7u EUR 1,8 million dans le cadre de l\u2019initiative Innovative Health (<a href=\"https:\/\/www.ihi.europa.eu\/\">IHI<\/a>) de l&rsquo;Union europ\u00e9enne. Ce financement soutient sa participation \u00e0 BRECISE, un consortium de recherche paneurop\u00e9en visant \u00e0 transformer le diagnostic et le traitement du cancer gr\u00e2ce \u00e0 l&rsquo;int\u00e9gration du s\u00e9quen\u00e7age de nouvelle g\u00e9n\u00e9ration (NGS) et de l&rsquo;intelligence artificielle.<\/p>\n\n\n\n<p>BRECISE a \u00e9t\u00e9 officiellement lanc\u00e9 \u00e0 Madrid lors du congr\u00e8s de l&rsquo;European Association of Urology et rassemble des partenaires du monde universitaire, des institutions cliniques et de l&rsquo;industrie. Cofinanc\u00e9e dans le cadre d&rsquo;Horizon Europe, l&rsquo;initiative vise \u00e0 acc\u00e9l\u00e9rer la validation de mod\u00e8les de biomarqueurs afin de soutenir une m\u00e9decine plus personnalis\u00e9e, en particulier pour les cancers de la prostate et de la vessie.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Renforcer l&rsquo;\u00e9cosyst\u00e8me europ\u00e9en de l&rsquo;innovation dans le domaine des soins contre le cancer<\/h4>\n\n\n\n<p>Dans le cadre de ce projet, Novigenix fera progresser sa plateforme LITOSeek, une technologie de biopsie liquide qui combine des donn\u00e9es transcriptomiques et g\u00e9nomiques issues d&rsquo;\u00e9chantillons sanguins. Gr\u00e2ce \u00e0 des analyses bas\u00e9es sur l&rsquo;IA, LITOSeek vise \u00e0 am\u00e9liorer la pr\u00e9diction de la r\u00e9ponse des patients aux immunoth\u00e9rapies, \u00e0 identifier les effets ind\u00e9sirables potentiels et \u00e0 aider les entreprises biopharmaceutiques \u00e0 optimiser la s\u00e9lection des patients pour les essais cliniques. Ces capacit\u00e9s pourraient conduire \u00e0 des traitements plus efficaces tout en r\u00e9duisant les complications et les inefficacit\u00e9s dans le d\u00e9veloppement des m\u00e9dicaments.<\/p>\n\n\n\n<p>Ce financement permettra \u00e0 Novigenix de passer du d\u00e9veloppement \u00e0 l&rsquo;\u00e9chelle de la recherche \u00e0 l&rsquo;industrialisation, en s&rsquo;assurant que la plateforme r\u00e9pond aux normes requises pour une adoption clinique dans les syst\u00e8mes de sant\u00e9 europ\u00e9ens. La contribution de l&rsquo;entreprise refl\u00e8te plus de dix ans d&rsquo;expertise dans l&rsquo;int\u00e9gration de donn\u00e9es multi-omiques et les diagnostics bas\u00e9s sur l&rsquo;IA.<\/p>\n\n\n\n<p>En participant \u00e0 BRECISE, Novigenix renforce la pr\u00e9sence de la Suisse occidentale dans les \u00e9cosyst\u00e8mes d&rsquo;innovation europ\u00e9ens et souligne l&rsquo;importance strat\u00e9gique de la collaboration transfrontali\u00e8re pour faire progresser la m\u00e9decine de pr\u00e9cision. Le projet d\u00e9montre comment les technologies \u00e9mergentes peuvent apporter des am\u00e9liorations tangibles aux soins aux patients et contribuer \u00e0 l&rsquo;\u00e9volution de l&rsquo;oncologie en Europe.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La start-up medtech Novigenix a re\u00e7u EUR 1,8 million de l&rsquo;initiative Innovative Health de l&rsquo;UE pour soutenir l&rsquo;industrialisation de sa plateforme de biopsie liquide bas\u00e9e sur l&rsquo;IA dans le cadre d&rsquo;une importante collaboration internationale de recherche sur le cancer. <\/p>\n","protected":false},"author":6,"featured_media":32694,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1179,1260,1169,1148,1188,1140],"class_list":["post-32697","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-artificial-intelligence-fr-2","tag-biometrics-fr-2","tag-biotech-fr-2","tag-financing-fr-2","tag-healthcare-fr-2","tag-oncology-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Novigenix obtient EUR 1,8 million pour sa plateforme d&#039;oncologie<\/title>\n<meta name=\"description\" content=\"Novigenix a re\u00e7u EUR 1,8 million pour soutenir l&#039;industrialisation de sa plateforme de biopsie liquide bas\u00e9e sur l&#039;IA.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novigenix obtient EUR 1,8 million pour sa plateforme d&#039;oncologie\" \/>\n<meta property=\"og:description\" content=\"Novigenix a re\u00e7u EUR 1,8 million pour soutenir l&#039;industrialisation de sa plateforme de biopsie liquide bas\u00e9e sur l&#039;IA.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-09T10:26:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-09T10:29:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2025\/04\/Novigenix-1180x811-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Novigenix obtient EUR 1,8 million pour d\u00e9velopper sa plateforme d&rsquo;oncologie de pr\u00e9cision\",\"datePublished\":\"2025-04-09T10:26:22+00:00\",\"dateModified\":\"2025-04-09T10:29:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/\"},\"wordCount\":425,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/04\/Novigenix-1180x811-1.jpeg\",\"keywords\":[\"Artificial Intelligence\",\"Biometrics\",\"Biotech\",\"Financing\",\"Healthcare\",\"Oncology\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/\",\"name\":\"Novigenix obtient EUR 1,8 million pour sa plateforme d'oncologie\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/04\/Novigenix-1180x811-1.jpeg\",\"datePublished\":\"2025-04-09T10:26:22+00:00\",\"dateModified\":\"2025-04-09T10:29:09+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Novigenix a re\u00e7u EUR 1,8 million pour soutenir l'industrialisation de sa plateforme de biopsie liquide bas\u00e9e sur l'IA.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/04\/Novigenix-1180x811-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/04\/Novigenix-1180x811-1.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"Bas\u00e9e sur le campus Biop\u00f4le \u00e0 Lausanne, Novigenix contribue au projet BRECISE financ\u00e9 par l'UE avec sa technologie de biopsie liquide pr\u00e9dictive. | \u00a9 Novigenix\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novigenix obtient EUR 1,8 million pour d\u00e9velopper sa plateforme d&#8217;oncologie de pr\u00e9cision\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novigenix obtient EUR 1,8 million pour sa plateforme d'oncologie","description":"Novigenix a re\u00e7u EUR 1,8 million pour soutenir l'industrialisation de sa plateforme de biopsie liquide bas\u00e9e sur l'IA.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/","og_locale":"fr_FR","og_type":"article","og_title":"Novigenix obtient EUR 1,8 million pour sa plateforme d'oncologie","og_description":"Novigenix a re\u00e7u EUR 1,8 million pour soutenir l'industrialisation de sa plateforme de biopsie liquide bas\u00e9e sur l'IA.","og_url":"https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2025-04-09T10:26:22+00:00","article_modified_time":"2025-04-09T10:29:09+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/04\/Novigenix-1180x811-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Novigenix obtient EUR 1,8 million pour d\u00e9velopper sa plateforme d&rsquo;oncologie de pr\u00e9cision","datePublished":"2025-04-09T10:26:22+00:00","dateModified":"2025-04-09T10:29:09+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/"},"wordCount":425,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/04\/Novigenix-1180x811-1.jpeg","keywords":["Artificial Intelligence","Biometrics","Biotech","Financing","Healthcare","Oncology"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/","url":"https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/","name":"Novigenix obtient EUR 1,8 million pour sa plateforme d'oncologie","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/04\/Novigenix-1180x811-1.jpeg","datePublished":"2025-04-09T10:26:22+00:00","dateModified":"2025-04-09T10:29:09+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Novigenix a re\u00e7u EUR 1,8 million pour soutenir l'industrialisation de sa plateforme de biopsie liquide bas\u00e9e sur l'IA.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/04\/Novigenix-1180x811-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/04\/Novigenix-1180x811-1.jpeg","width":1180,"height":811,"caption":"Bas\u00e9e sur le campus Biop\u00f4le \u00e0 Lausanne, Novigenix contribue au projet BRECISE financ\u00e9 par l'UE avec sa technologie de biopsie liquide pr\u00e9dictive. | \u00a9 Novigenix"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/novigenix-obtient-eur-18-million-pour-developper-sa-plateforme-doncologie-de-precision\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Novigenix obtient EUR 1,8 million pour d\u00e9velopper sa plateforme d&#8217;oncologie de pr\u00e9cision"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/32697","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=32697"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/32697\/revisions"}],"predecessor-version":[{"id":32699,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/32697\/revisions\/32699"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/32694"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=32697"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=32697"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=32697"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}